<SEC-DOCUMENT>0001070081-20-000137.txt : 20201029
<SEC-HEADER>0001070081-20-000137.hdr.sgml : 20201029
<ACCEPTANCE-DATETIME>20201029160629
ACCESSION NUMBER:		0001070081-20-000137
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20201029
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201029
DATE AS OF CHANGE:		20201029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		201272662

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ptct-20201029x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7556.35618 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/29/2020 7:50:50 PM -->
      <!-- iXBRL Library version: 1.0.7556.35625 -->
      <!-- iXBRL Service Job ID: fd1823c7-e30c-4923-a28f-eed32942e2dc -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20201029" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityCentralIndexKey" id="Tc_KEk52bg5G0Sx5_xIdBpa4g_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:AmendmentFlag" id="Tc_xBMvo-B1iUKup9NTeJtNdQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20201029.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-29</xbrli:startDate><xbrli:endDate>2020-10-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1c2b8121_8120_4d2c_bf9a_3bd62a26e6df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:DocumentType" id="Narr_7qO3fjwXV0KIeSuZpwqUmA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_cIW9yeZETUKSwNdi2e5PmA"><b style="font-size:9pt;font-weight:bold;">October 29, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityRegistrantName" id="Narr_AzoLAykvZk6zBLDX1j7EfQ"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_i6zjMA_efUOVGwmAhfnKHw_2_0"></a><a id="Tc_hKZBe202MkmG0cClKsp_Vg_2_2"></a><a id="Tc_jlVfi320GECLHl4kUOY0yw_2_4"></a><a id="Tc_T44qdoxtC0-hu_IC4uG5_g_3_0"></a><a id="Tc_g9-Jz0UsmUOQ5oe7vyvXpA_3_2"></a><a id="Tc_z1HquGD5rEaKT2dxUTEdrw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_p8xbjfyCH02xGgqeUh2LGw_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityFileNumber" id="Tc_6JPbpZGr6Em3bjRUdtHJxA_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityTaxIdentificationNumber" id="Tc_rVHeY_Hzz0ijyOkG_clZhw_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_DTJYm-L3-EiZCQcOkm1w-Q_2_0"></a><a id="Tc_XY_iRhlL-0SHDDkv828Ymw_3_0"></a><a id="Tc_4Sl7IWM87UOYgEeq-uo2YQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityAddressAddressLine1" id="Tc_2oPuiUZWB0SCCHpbfY2H5g_1_0"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityAddressCityOrTown" id="Narr_cAJrcUxuFESpQFjvOatARg"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityAddressStateOrProvince" id="Narr_kSSH0z48C0OliYenQyhyLQ"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:EntityAddressPostalZipCode" id="Tc_4qkAVvpa9U-KRpPf-U0Y_A_2_2"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:CityAreaCode" id="Narr_fbfQb42UAEWSxsW15JwXhQ"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:LocalPhoneNumber" id="Narr_MIkbaCH7eUmtuJCZwvVbEw"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_rdJyMNmBwkqVf8Twdcf3vw"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_xwRAeZzk_kC5acEc-D6YYg"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_6-9GfWB790Syc4fPAzCfpQ"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_XDJ3ZWldcE-UdDhwvliqUA"><span style="color:#000000;font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_uOci-DUGQk6NkA2U-GtoNg_1_0"></a><a id="Tc_Nxhs1bSQVk6k9MfU2nr83A_1_2"></a><a id="Tc__0LvzWaGRkajIGI7q8DdIw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:Security12bTitle" id="Tc_OHf_wCgqQkqgjF3ii_OGig_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" name="dei:TradingSymbol" id="Tc_gyO6tX1ZCUiGbtMvi8Ycjw_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_PluIyr07uUmCxb_39ZRq0A_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_pRVgWMHq0EW_KZgpGDM7Qg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_32cf1bf0_31ef_44e6_932a_f84b2d4e95e6"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.02.&#160;Results of Operations and Financial Condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October 29, 2020, PTC Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September&#160;30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K (this &quot;Report&quot;) and is incorporated by reference into this Item&#160;2.02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f1f1883b_0361_4efe_b726_ccb5a9303f84"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.01.&#160;Regulation FD Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will host a conference call on October 29, 2020 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended September&#160;30, 2020, as well as other corporate highlights and updates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit&#160;99.1 hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00c374eb_0118_4061_8a8d_70ded480bd97"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptct-20201029ex99135e319.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press Release, dated October 29, 2020 issued by PTC Therapeutics,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page&#160;from this Current Report on Form&#160;8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_63e2b05b_6c05_4329_ae5b_8f5aebdbaf1a"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 29, 2020</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Emily Hill</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emily Hill</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ptct-20201029ex99135e319.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/29/2020 07:50:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">TM</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> makes rapid progress with multiple international approvals and strong U.S. launch -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase - </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- Initiated registration-directed trial with vatiquinone (PTC743) for mitochondrial epilepsy -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SOUTH PLAINFIELD, N.J., </b><font style="font-family:'Arial','Helvetica','sans-serif';">October 29, 2020 &#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the third quarter ending September 30, 2020 and provided a corporate update.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;I am very pleased by the rapid progress that we have made this quarter with the approval and strong U.S. launch of Evrysdi for spinal muscular atrophy and the continued growth across our global Duchenne muscular dystrophy franchise,&#8221; said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;We have also made significant advances across our clinical pipeline with a registration-directed trial in mitochondrial epilepsy initiated this quarter and an additional registration-directed trial in Friedreich ataxia to initiate before year end. The mission at PTC has always been to bring therapies to patients with high unmet medical need through investment in innovative technologies and we believe we are well positioned to bring long-term value for all of our stakeholders.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Third Quarter and Other Corporate Updates</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">In August 2020, the U.S. Food and Drug Administration (FDA) approved Evrysdi (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older. In the early stages of launch, patients across a broad age range and SMA type have been treated. In October 2020, there were additional approvals in Brazil, Chile and Ukraine, further expanding the global reach of Evrysdi. Evrysdi is a product of the SMA collaboration between PTC, the SMA Foundation, and Roche.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Also in August 2020, the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) filed by Roche for Evrysdi for the treatment of SMA. The EMA previously granted PRIME (PRIority MEdicines) designation to risdiplam for the treatment of SMA, providing a pathway for accelerated evaluation by the agency. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The EMA&#8217;s acceptance of the MAA filed by Roche for Evrysdi for the treatment of SMA triggered a $15 million milestone payment to PTC and the first commercial sale of Evrysdi in the U.S. triggered a $20 million milestone payment to PTC. As a result, PTC recognized $35.0 million in collaboration revenue associated with Roche milestone events in the third quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">In October 2020, Chugai Pharmaceutical, Co. Ltd, a member of the Roche group, announced that a new drug application for Evrysdi for the treatment of SMA was filed in Japan. Risdiplam received orphan drug designation from the Japan Ministry of Health, Labour and Welfare and the application is subject to a priority review. The filing in Japan triggered a $7.5 million milestone payment to PTC in the fourth quarter of 2020. Roche is executing an aggressive global regulatory strategy and now has over 20 additional applications filed for Evrysdi around the world.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">PTC has multiple aromatic L-amino acid decarboxylase (AADC) deficiency patient finding initiatives ongoing which continue to progress even amid COVID-19. PTC has expanded the number of </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">programs globally and in September 2020. PTC launched its newest program, PTC PINPOINT. The program offers testing at no charge to patients which can lead to an earlier diagnosis and treatment.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Third Quarter Clinical Updates</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Two-year data from Part 1 of the Evrysdi FIREFISH study were presented at the 25th International Annual Congress of the World Muscle Society (WMS). The data demonstrated that infants treated with Evrysdi continued to improve and achieve motor milestones. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">A registration-directed Phase 2/3 placebo-controlled trial to evaluate vatiquinone (PTC743) in children with mitochondrial epilepsy began enrollment in October 2020. This MIT-E trial is targeting the highly morbid and life-threatening symptom of refractory seizures in children with inherited mitochondrial disease. Vatiquinone, developed from PTC&#8217;s Bio-e platform, is an investigational oral small molecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways that underpin neurological disease pathology including epilepsy. The FDA has granted vatiquinone orphan drug designation and pediatric rare disease designation for mitochondrial epilepsy. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The Phase 3 vatiquinone Friedreich ataxia trial (MOVE-FA) is expected to initiate in the fourth quarter of 2020 and the Phase 3 PTC923 phenylketonuria (PKU) trial is expected to initiate in mid-2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Muscle biopsies have been completed on all 20 enrolled subjects in PTC&#8217;s Translarna</font><sup style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;text-align:justify;vertical-align:top;">TM</sup><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;"> (ataluren) dystrophin study (Study 045). The samples from these biopsies are in the process of being analyzed and PTC expects to report top-line results in the first quarter of 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">A Phase 1 study of PTC518 in healthy volunteers is expected to begin enrollment this quarter. PTC518 is another candidate from PTC&#8217;s validated splicing platform and is being developed for the treatment of Huntington disease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The Phase 1 single ascending dose study for PTC857 has been completed and dosing in the multiple ascending dose study is expected to be completed by the end of 2020. PTC857 was developed from the Bio-e platform with the potential to address multiple CNS disorders, with the first planned indication being glucocerebrosidase (GBA) Parkinson&#8217;s disease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">A Phase 2/3 clinical trial for PTC299 for COVID-19 (FITE19) continues to enroll patients. PTC is expecting Stage 1 of this two-stage trial to be completed by the end of 2020 and continues to anticipate reporting top-line results from both stages in the first half of 2021. Stage 1 of this study is being conducted in the U.S., Brazil, Spain, and Australia.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Due to COVID-19 related delays, PTC expects the EMA&#8217;s Committee for Medicinal Products for Human Use final opinion for the AADC deficiency application in the first half of 2021. &#160;PTC expects the biologics license application (BLA) for AADC deficiency to be submitted to the FDA in the first half of 2021.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Financial Highlights</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Total revenue was $118.4 million for the third quarter of 2020, compared to $71.4 million for the third quarter of 2019, a 66% year-over-year increase, Total revenue includes net product revenue of $82.7 million and collaboration and royalty revenue of $35.7 million in the third quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Total net product revenue across the commercial portfolio was $82.7 million for the third quarter of 2020, a 16% year-over-year increase.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The Duchenne muscular dystrophy franchise continued to show strong performance in the third quarter with a 15% year-over-year increase. Emflaza</font><sup style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;text-align:justify;vertical-align:top;">&#174;</sup><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;"> continued its momentum from the second quarter of 2020 into the third quarter of 2020 driven by new patient prescriptions and ongoing </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">operational improvements in PTC&#8217;s commercial business. New Duchenne patients continue to be identified in Europe, LATAM and other key markets for Translarna. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Translarna net product revenue was $43.4 million for the third quarter of 2020, compared to $48.3 million for the third quarter of 2019, a 10% year-over-year </font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">decrease. Revenue for the third quarter of 2020 was impacted by the timing of a group purchase order from Brazil, which is the primary driver for the year-over-year decrease compared to the third quarter of 2019. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">In October, PTC entered into a purchase agreement with the Brazil Ministry of Health for Translarna. The initial shipment was received by the Brazil Ministry of Health in October 2020 with the additional shipment expected in the first half of 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Emflaza net product revenue was $38.5 million for the third quarter of 2020, compared to $22.9 million for the third quarter of 2019. </font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Growth in net product revenue was driven by new patient prescriptions and continued operational improvements and efficiencies in the commercial business.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Roche reported initial Evrysdi August and September sales of approximately CHF 8 million. The acceptance of the MAA filed by Roche for Evrysdi for the treatment of SMA triggered a $15 million milestone payment to PTC and the first commercial sale of Evrysdi in the U.S. triggered a $20 million milestone payment to PTC. As a result, PTC recognized $35.0 million in collaboration revenue associated with Roche milestone events in the third quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Based on U.S. GAAP (Generally Accepted Accounting Principles), research and development (R&amp;D) expenses were $93.0 million for the third quarter of 2020, compared to $63.1 million for the third quarter of 2019. The increase in R&amp;D expenses reflects costs associated with advancing the gene therapy and Bio-e platforms, increased investment in research programs, and advancement of the clinical pipeline.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Non-GAAP R&amp;D expenses were $83.8 million for the third quarter of 2020, excluding $9.2 million in non-cash, stock-based compensation expense, compared to $58.1 million for the third quarter of 2019, excluding $5.0 million in non-cash, stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">GAAP selling, general and administrative (SG&amp;A) expenses were $57.8 million for the third quarter of 2020, compared to $49.3 million for the third quarter of 2019. T</font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">he increase reflects continued investment to support PTC&#8217;s commercial activities including the expanding commercial portfolio.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Non-GAAP SG&amp;A expenses were $50.2 million for the third quarter of 2020, excluding $7.6 million in non-cash, stock-based compensation expense, compared to $43.8 million for the third quarter of 2019, excluding $5.5 million in non-cash, stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Change in the fair value of deferred and contingent consideration was $8.4 million for the third quarter of 2020, compared to $9.5 million for the third quarter of 2019. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC&#39;s acquisition of Agilis, which closed in August 2018.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Net loss was $69.7 million for the third quarter of 2020, compared to net loss of $60.0 million for the third quarter of 2019.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Cash, cash equivalents and marketable securities were $1,141.0 million as of September 30, 2020, compared to $686.6 million as of December 31, 2019. The cash, cash equivalents and marketable securities balance as of September 30, 2020 includes $650.0 million in consideration received related to the July 17, 2020 Royalty Purchase Agreement between PTC and RPI 2019 Intermediate Finance Trust (&#8220;RPI&#8221;).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">Shares issued and outstanding as of September 30, 2020 were 67,809,560.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:103.4%;"><tr style="height:10.8pt;"><td colspan="5" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics, Inc.</b></p></td></tr><tr style="height:9.45pt;"><td colspan="5" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p></td></tr><tr style="height:15pt;"><td colspan="5" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">(In thousands, except share and per share data)</p></td></tr><tr style="height:6.7pt;"><td colspan="5" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td colspan="2" style="vertical-align:top;width:27.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,</b></p></td><td colspan="2" style="vertical-align:top;width:26.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,</b></p></td></tr><tr style="height:13.05pt;"><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:8.05pt;"><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:top;width:15.35%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:13.94%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:13pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Net product revenue</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 82,708</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 71,369</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 226,143</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 209,899</p></td></tr><tr style="height:8.5pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Collaboration and grant revenue</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">35,000</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">47</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">35,063</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">622</p></td></tr><tr style="height:9.4pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Royalty revenue</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">696</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 36pt;"><font style="white-space:pre-wrap;">   - </font></p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">696</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 36pt;"><font style="white-space:pre-wrap;">    -</font></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Total revenues</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">118,404</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">71,416 </p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">261,902</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">210,521</p></td></tr><tr style="height:9.85pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:top;width:15.35%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:13.94%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:11.2pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Cost of product sales</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">4,667</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">3,006</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">14,056</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">8,593</p></td></tr><tr style="height:11.65pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Amortization of acquired intangible asset</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">9,630</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">7,025</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">26,309</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">19,677</p></td></tr><tr style="height:12.55pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Research and development (1)</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">92,998</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">63,076</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">359,630</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">175,621</p></td></tr><tr style="height:8.5pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Selling, general and administrative (2)</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">57,840</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">49,284</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">169,708</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">139,044</p></td></tr><tr style="height:22.9pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Change in the fair value of deferred and contingent consideration</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">8,400</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">9,500</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">16,980</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">35,960</p></td></tr><tr style="height:9.9pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Settlement of deferred and contingent consideration</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">10,613</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">-</p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">173,535</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">131,891</p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">597,296</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">378,895</p></td></tr><tr style="height:9.85pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Loss from operations</p></td><td style="vertical-align:top;width:15.35%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(55,131)</p></td><td style="vertical-align:top;width:12.59%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(60,475)</p></td><td style="vertical-align:top;width:13.94%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(335,394)</p></td><td style="vertical-align:top;width:12.54%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(168,374)</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Interest expense, net</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(21,039)</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(2,666)</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(32,060)</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(7,028)</p></td></tr><tr style="height:11.65pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Other income, net</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">28,766</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">2,800</p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">26,242</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">2,509</p></td></tr><tr style="height:12.1pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Loss before income tax expense</p></td><td style="vertical-align:top;width:15.35%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(47,404)</p></td><td style="vertical-align:top;width:12.59%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(60,341)</p></td><td style="vertical-align:top;width:13.94%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(341,212)</p></td><td style="vertical-align:top;width:12.54%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(172,893)</p></td></tr><tr style="height:8.5pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Income tax (expense) benefit</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(22,288)</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">344</p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(22,594)</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">(1,006)</p></td></tr><tr style="height:9.4pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:top;width:15.35%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (69,692)</p></td><td style="vertical-align:top;width:12.59%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (59,997)</p></td><td style="vertical-align:top;width:13.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (363,806)</p></td><td style="vertical-align:top;width:12.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (173,899)</p></td></tr><tr style="height:5.35pt;"><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:15.35%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:12.59%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.94%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:12.54%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr style="height:11.2pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Weighted-average shares outstanding:</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:11.65pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Basic and diluted (in shares)</p></td><td style="vertical-align:top;width:15.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">67,641,171</p></td><td style="vertical-align:top;width:12.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">56,463,528</p></td><td style="vertical-align:top;width:13.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">65,068,281</p></td><td style="vertical-align:top;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">57,798,968</p></td></tr><tr style="height:12pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</p></td><td style="vertical-align:top;width:15.35%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (1.03)</p></td><td style="vertical-align:top;width:12.59%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (1.06)</p></td><td style="vertical-align:top;width:13.94%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (5.59)</p></td><td style="vertical-align:top;width:12.54%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ (3.01)</p></td></tr><tr style="height:9.85pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:15.35%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:13.94%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(1) Research and development reconciliation</b></p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:12.15pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">GAAP research and development</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 92,998</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 63,076</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 359,630</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 175,621</p></td></tr><tr style="height:9.9pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Less: share-based compensation expense</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">9,220</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">4,988</p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">25,961</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">15,191</p></td></tr><tr style="height:12.15pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Non-GAAP research and development</b></p></td><td style="vertical-align:top;width:15.35%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 83,778</p></td><td style="vertical-align:top;width:12.59%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 58,088</p></td><td style="vertical-align:top;width:13.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 333,669</p></td><td style="vertical-align:top;width:12.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 160,430</p></td></tr><tr style="height:12.1pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:15.35%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:13.94%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(2) Selling, general and administrative reconciliation</b></p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:11.25pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;">GAAP selling, general and administrative</p></td><td style="vertical-align:top;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 57,840</p></td><td style="vertical-align:top;width:12.59%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 49,284</p></td><td style="vertical-align:top;width:13.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 169,708</p></td><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 139,044</p></td></tr><tr style="height:9pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;">Less: share-based compensation expense</p></td><td style="vertical-align:top;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">7,559</p></td><td style="vertical-align:top;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">5,496</p></td><td style="vertical-align:top;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">22,948</p></td><td style="vertical-align:top;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">15,477</p></td></tr><tr style="height:8.5pt;"><td style="vertical-align:top;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Non-GAAP selling, general and administrative </b></p></td><td style="vertical-align:top;width:15.35%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 50,281</p></td><td style="vertical-align:top;width:12.59%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 43,788</p></td><td style="vertical-align:top;width:13.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 146,760</p></td><td style="vertical-align:top;width:12.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 123,567</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:103.4%;"><tr style="height:8.5pt;"><td colspan="3" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics, Inc.</b></p></td></tr><tr style="height:10.75pt;"><td colspan="3" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Summary Consolidated Balance Sheets</b></p></td></tr><tr style="height:8.05pt;"><td colspan="3" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands, except share data)</p></td></tr><tr style="height:5.8pt;"><td colspan="3" style="vertical-align:top;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:11.65pt;"><td style="vertical-align:top;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:17.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">September 30, 2020</b></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">December 31, 2019</b></p></td></tr><tr style="height:11.2pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Cash, cash equivalents and marketable securities</p></td><td style="vertical-align:top;width:17.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 1,141,019</p></td><td style="vertical-align:top;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 686,563</p></td></tr><tr style="height:8.5pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:top;width:17.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ 2,181,059</b></p></td><td style="vertical-align:top;width:16.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ 1,623,782</b></p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:17.94%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.96%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr style="height:12.55pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Total debt</p></td><td style="vertical-align:top;width:17.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 302,971</p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 313,859</p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Total deferred revenue</p></td><td style="vertical-align:top;width:17.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">5,992</p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">11,657</p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Total liability for sale of future royalties </p></td><td style="vertical-align:top;width:17.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">664,258</p></td><td style="vertical-align:top;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">- </p></td></tr><tr style="height:12.55pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:top;width:17.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ 1,670,105 </b></p></td><td style="vertical-align:top;width:16.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ 1,029,452 </b></p></td></tr><tr style="height:8.95pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:17.94%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.96%;border-top:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td></tr><tr style="height:45.85pt;"><td style="vertical-align:top;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;">Common stock, $0.001 par value. Authorized 125,000,000 shares; issued and outstanding 67,809,560 shares at September&#160;30,&#160;2020. Authorized 125,000,000 shares; issued and outstanding 61,935,870 shares at December&#160;31,&#160;2019.</p></td><td style="vertical-align:top;width:17.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 510,954 </p></td><td style="vertical-align:top;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">$ 594,330</p></td></tr><tr style="height:9.4pt;"><td style="vertical-align:top;white-space:nowrap;width:65.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#39; equity</b></p></td><td style="vertical-align:top;width:17.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ 2,181,059 </b></p></td><td style="vertical-align:top;width:16.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ 1,623,782</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Conference Call and Webcast </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC will host a conference call to discuss the third quarter of 2020 operational and financial today at 4:30 pm ET and can be access by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode </font><font style="font-size:11pt;">7096445</font><font style="font-family:'Arial','Helvetica','sans-serif';">. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Lisa Hayes</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (732) 354 8687</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">lhayes@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Jane Baj</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9167</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">jbaj@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters; expectations with respect to PTC&#39;s gene therapy platform, including any potential regulatory submissions and manufacturing capabilities; advancement of PTC&#39;s joint collaboration program in SMA, including any potential regulatory submissions, commercialization or royalty or milestone payments; PTC&#39;s expectations with respect to the licensing, regulatory submissions and commercialization of its products and product candidates; the timing with respect to orders for PTC&#39;s products; expectations with respect to the impacts of the COVID-19 pandemic and related response measures; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">identified by the words &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC&#39;s gene therapy platform, including any potential regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of ongoing studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions and potential commercialization with respect to Evrysdi; PTC&#39;s ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC&#39;s ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC&#39;s ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi and Waylivra</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">TM</sup><font style="font-family:'Arial','Helvetica','sans-serif';">; the enrollment, conduct and results of PTC&#39;s PTC299 clinical trial for COVID-19; expectations with respect to the COVID-19 pandemic and related response measures and their effects on PTC&#39;s business, operations, clinical trials, potential regulatory submissions and approvals, and PTC&#39;s collaborators, contract research organizations, suppliers and manufacturers; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; PTC&#39;s ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Evrysdi, Tegsedi, Waylivra or PTC-AADC.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.<br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptct-20201029.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 7:50:53 PM-->
<!--Modified on: 10/29/2020 7:50:53 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20201029" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20201029">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptct-20201029_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptct-20201029_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ptct-20201029_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 7:50:53 PM-->
<!--Modified on: 10/29/2020 7:50:53 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ptct-20201029_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/29/2020 7:50:53 PM-->
<!--Modified on: 10/29/2020 7:50:53 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptct-20201029.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637395978538818897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637395978538818897" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637395978538818897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637395978538818897" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637395978538818897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637395978538818897" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637395978538828889" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637395978538828889" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637395978538828889" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637395978538828889" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637395978538828889" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637395978538828889" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637395978538828889" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637395978538828889" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637395978538828889" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_637395978538828889" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_637395978538828889" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637395978538828889" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637395978538828889" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637395978538828889" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637395978538828889" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637395978538828889" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637395978538838897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637395978538838897" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637395978538838897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637395978538838897" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637395978538838897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637395978538838897" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637395978538838897" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637395978538838897" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>ptct-20201029x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20201029.xsd" xlink:type="simple"/>
    <context id="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-10-29</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_KEk52bg5G0Sx5_xIdBpa4g_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_xBMvo-B1iUKup9NTeJtNdQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_7qO3fjwXV0KIeSuZpwqUmA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_cIW9yeZETUKSwNdi2e5PmA">2020-10-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_AzoLAykvZk6zBLDX1j7EfQ">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_p8xbjfyCH02xGgqeUh2LGw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_6JPbpZGr6Em3bjRUdtHJxA_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_rVHeY_Hzz0ijyOkG_clZhw_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_2oPuiUZWB0SCCHpbfY2H5g_1_0">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_cAJrcUxuFESpQFjvOatARg">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_kSSH0z48C0OliYenQyhyLQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_4qkAVvpa9U-KRpPf-U0Y_A_2_2">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_fbfQb42UAEWSxsW15JwXhQ">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_MIkbaCH7eUmtuJCZwvVbEw">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_rdJyMNmBwkqVf8Twdcf3vw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_xwRAeZzk_kC5acEc-D6YYg">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_6-9GfWB790Syc4fPAzCfpQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_XDJ3ZWldcE-UdDhwvliqUA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_OHf_wCgqQkqgjF3ii_OGig_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_gyO6tX1ZCUiGbtMvi8Ycjw_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Tc_PluIyr07uUmCxb_39ZRq0A_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ"
      id="Narr_pRVgWMHq0EW_KZgpGDM7Qg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140133115929976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 29,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9'M2#PIY49M"8TQ-E1=88O3.O:21\*5=
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M,:@W6]5C6)>E:H\_A?<HN9\;[O\2Q0]02P,$%     @ SH!=49>*NQS
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M=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3
MQFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=
MR_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D
M&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&
ML&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @
MSH!=420>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ SH!=40=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #.@%U1'\=+
M$.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #.@%U1F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,Z 75'#(.L /P0  &X0
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #.@%U1@ZFE ]0!   R!@  #0              @ &"#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,Z 75&7BKL<P    !,"   +
M          "  8$.  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,Z 75$<.&7J
M/P$  #P"   /              "  6H/  !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " #.@%U1)!Z;HJT   #X 0  &@              @ '6$   >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #.@%U199!YDAD!
M  #/ P  $P              @ &[$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     "0 ) #X"   %$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ptct-20201029x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ptct-20201029x8k.htm">ptct-20201029x8k.htm</File>
    <File>ptct-20201029.xsd</File>
    <File>ptct-20201029_lab.xml</File>
    <File>ptct-20201029_pre.xml</File>
    <File>ptct-20201029ex99135e319.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptct-20201029x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ptct-20201029x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20201029_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20201029_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20201029.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20201029",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20201029x8k.htm",
      "contextRef": "Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20201029x8k.htm",
      "contextRef": "Duration_10_29_2020_To_10_29_2020_HQiYITbNtECmIIZ5876ZCQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001070081-20-000137-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-20-000137-xbrl.zip
M4$L#!!0    ( ,Z 75%']N<^6 ,  .H+   1    <'1C="TR,#(P,3 R.2YX
M<V2U5M]OVC 0?I^T_\'C/7$"@A8$K=9UDR;1;>HZJ6^3<0Q82^S,=@K][W<V
M<?CE4#IM3P1_=]]]=^>[9'R]+G+TQ)3F4DPZ:9QT$!-49EPL)IU*1T13SCO7
M5V_?C-]%T>/-_11EDE8%$P91Q8AA&5IQLT0/LBR)0'=,*9[GZ$;Q;,$0&L:#
M^*+?'\2]_B"]1%%4,]T0#9Y2($?9C=,&^5"S2C%":8*[0]Q-N@FZ&/634;^'
MOMTUEG<@<\Y?-EWK;*3IDA4$&:(6S'PA!=,EH6S261I3CC!>K59Q:>B,RYC*
MPM&D27?80<08Q6>589^D*F[9G%2Y@<*(WQ7)77"H5\YL.?8,=F HL- CT+ 7
M;-6+I5I H"3%CW?3[TZ>-^;BB6G3V*]G*H\UH_%"/N$-!HYI+TK2J)=ZIXSQ
ML < +J%]<^CM@I"R<9D3/7.2:B#@HI6)S'/)]+%3 X4C*9F'O#P2<%)LOE<O
MEU%=L0$&M"DL -E!K6J[/MZ WE1((:HB3)L9A6T"&(PBL&**4^]'*Z5@*)[#
MY?6H;<G%?A+KO#6''GZ<<O&KD48XU6%^!P7(;<E;ZMI @<)260FCVG+9@(%H
ME5&MN0PQH#NR@H("4G(HP(D"67@&:\*;LS5=AF5;),!_1K/W&[T^4E2/:3H<
M#K%#FS0Y#6L!P)8O/9J!ELGQ2$@_6]A->*+NMLFX-FN4F5*U2 /$:KO<#W/&
MBO,[C+^\PR(NM"&"LMT!Y2?:?&@/:]B\N)=AK2/D%CL10AIBX/7ESOQI67(Q
ME_41'-K>C6RY'J#8R#[\N/_<%L:5];9^S?G?]R+[* PWSY^!6!4N9 =Q:,]9
MEHT4+R9C<RZX$YY +Q,4(4^P^TA$AC9L:(=NC \Y#NDK>+]^%5?NN51, Y?S
MM%NG]JY-3GE2DM,J_PO'K;)VO_K4=^6@67[\[]D<N=$;V3F9=#0ORMS>%G>V
M="\*>V<B?SE^0KHQW"5O8OE/W#_7[,,*U8$]!5'TB.5H-0")+)DR'(9YN[OP
M/TLK)[/7I@4N+/\_^8SQX9S5)_OSZ*814I/*(!'\[&K;!ILOMJFDCNR$B_W7
M;)W('D5I%_9;#*&]WM,RPA\-9PKP#C9R_Y4QVS[10J%UFY-]B+;>6PF;AFRX
MKOX 4$L#!!0    ( ,Z 75'W,>=[=04  ( \   5    <'1C="TR,#(P,3 R
M.5]L86(N>&ULU9OA;]HX&,:_GW3_PSONRYVT$$)%=T5MIY9U4W5T18/337<Z
M32$Q8%VPD6,*_/>SDYB2U X,>L%\:3/>)X_?Q_SF.)!>OE].(WA"+,:47-6\
M>J,&B 0TQ&1\59O'CA\'&-?>7__\T^4;Q_EZ^Z4+(0WF4T0X! SY'(6PP'P"
M SJ;^00>$&,XBN"6X7", "[JY_5WK=9Y_:QU[OT.CI,YW?JQ.),22"R;=6]=
MZ62NE+3!:[C-"[?9:#;@7;O5:+?.H/>P5CZ(-D=XNS3"Y+^V_#$4@X((3.+V
M,L97M0GGL[;K+A:+^N*L3ME8G-_PW*\/W7XP05/?P23F/@E0#82^'2<O=FG@
M\V2V-DY?#EFD#,[<]5A&A?R7HV2.?,GQFLZ95U_&82UK499W&$3)937DZQ,V
MQ2TW+:ZE+ZRS^-[%Q86;5&MBX@"RJ?.'*.J*(TA*;;Z:H:L:6G)$0B3;35YE
M-$(E[<JR^^PLO6F0,XSDQ%*F_"8,C5*_6,6)45 ?TR<W1#AYI^6!(P^<AI=-
MWB_BI6\=*HB^&<:<^0%7?DF*JYJN+B=EIYEVU[U+LQN6#^"S0 TF#K?,1Z9P
M RKXFG$G<52GCQB=ZEM-AZ.:XK=H&.V?)1>$H9C.68+][F_M9O^FN5[W*!1R
M@4'$^;/_ TU??U!KCT]"N",<\Q7<DQ%ET^3_)/RC1OKW,NWH_X=-M300OIK\
MA;+%J.F"*-(V:Y:"IFWQ8,ZD6^4H]1##-+PCX0=Q)2R)6M2= %S::$7*<B++
M<=/W>C!WJ:U8XD*0QI4AF*ZI'W&$/L^G0\0TR342B\$S!5+,%>N6XF9L<U_2
MLHNG=(34LF+&OJ QEM=JPC_[4]TJ9Y!9SYH^6)ZWO,9JY@RM'LC=LRM(VXK9
MNQ>WN&Q&6;)I['.QP';HG'"VZM#0C.*VLZPG<Z?8>5!+3[&:V]TZ/Q#CW"!O
M(1D&*(-L*)!C5<SVP%_>AV(+@4<X_:!BRX7<K+>>YRU1\R0;Q%8SO*WG ^D5
M]I#W/\Y6X"8,Q=S%V:\N)L@S3HE>:SVJ)1'SF&J$5B-:UN^!>&:>;]4!2'=X
M)%6OJ-GP'7'XR 9T0;9-1DYY*FB^C*<%\UEV"EAJNGTM**6UO-1+\^, F>PV
M'EF/T2=, O.^U2@_%30-0;5\%K2G *FIY=<B=;TK52,<!]<>C;D?_8UGI3=9
M!O&IH*H-J04UISP%3/4-OQ:DJ3L(^VIOFN0R?L.0;X"R4+880UV0]1>%&S5+
M4=.VN"]<R;59NE7+DGPT(.I-*#%_>*Z16,R4*9#BJEBWE"UCF_ORE1A"XECU
M'?-?#'..2(=.IW.2W;7'FLPFG<6TE493R&E%EG)7WNN^\&6ND+>M#, ^C7"
M.2;C![&M9-C7)=>*+$;/'$IQ]U)A*70EC>Y+W+,E*,_*<.LQ)$%'XNU+GNZ0
MSYRQQ]%(>W4M%5N,W_:0"D.STE(<=VAX7RR%M1-L>$-J#HG[L0"]C^,Y8C^$
MJ>Z4TX'5&-B [ O]:8!K;OO5\$V'. [%?13,Q;YBY36' \PCW:VP1F(QI:9
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M\-;C0G(;.W4;C\H]"(0[4K\GOW"4)TDD^ZF^-"%1=.6]"AA=RF3NY'T\,#:
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M>GVMFDH;/N^FY72?(/BY<?.N8^FB)XA[;MS$[99E.P_"X<Z8:/?Z%I]54'G
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MVK,ZZ"MO C]&R=C_]?\#4$L#!!0    ( ,Z 75&:]T.1@18  ,FN   4
M<'1C="TR,#(P,3 R.7@X:RYH=&WM/6E3X[JRWV_5^P]ZW'?/,%4X\9;%@>%6
M"!D(2P)99@:^N&1;3DP<VW@AR?SZUY+MX(1E"#M#ILXA7F2IU;M:+6GKOY.1
MC:Z('UBN\^V+D.._(.+HKF$Y_6]?>MWO7/G+?[?_A> ?^X/0UO]R'+)^[;2/
MD.'JT8@X(=)]@D-BH+$5#BJHZWH>=M Q\7W+MM&.;QE]DGRBY(JY4J%0S$F%
MHE!&'+>=K78'!U"+ZU22TD).6"Q22YJBA00^+RIYD1=Y5*H4>/@/G1PO?A#7
M=&1I/O:G:4_AVQP_ T0LW/Y1A_A7ED[0@:NAQFX%F890%B6]Q!&)USE9$24.
MBV63(\201$46B6CHF9K@9VL0 GH!Q4Y0,8CU;6T0AEXEGY]HOIT+B)[KNU=Y
M>,$ZP?$")PEK<?%9T?%XG!M+.=?OYP5%4?(36F52J&);SG"N)*N8EA5Y7LK3
MUQK@-"T^N5%^KF;Z=E84*C+">8"3>@OY^.6LZ*W 0D$A_^OXJ*,/R ASEA.$
MV-%GH%B3D ,$S'V9(L1R !)"29 /?>P$INN/< AD@TJ% L>7K]%4\4(]G*L$
M'FB6F]/=$4.JP(M*ILW;D?6G!D5.+%Y7<A?"!2E345K<)^:=!"KFX6T6X=8]
MM)PA<'MK0+"QO34B(4:T.$<N(^OJVYKN.B%((Q=./4!S<O=M+223,!\S37Y[
M*[1"FVQOY=/?N"[--:;;6X9UA8)P:I-O:R/L]RV'"UVO(O%>N FMYN'U7!G#
M"CP;3RN.ZQ!:P)I4:&W$CR\MPR .NX0"35 4OJ7'4$W"-L7*;N0S)*L"KXJ*
M2JFE=MWLW?ZI==;H:LVP7ALU&N>%<JEX7CM=0PX>T?:)5:D[T)%I#3KJ8[OA
M&&1R2*9KR#*^K75U]; ^+(A:O[#'=R8%==(P=CPL]U51%=:V>>!/OL3S96$K
M/P?C2X-<!95I4+7YW<;]&:B3G>,KE]L1K-YAY"G-+CD(F\:I*E%036P'Y :4
M^7DD RL1'U0W";:WJ"!7 B9X #9B@ET9,%:D\L*E@I&;!,9:\IIRS;>UP!IY
M-N6Q_'P=<7/9-MAMX$8^NV/<6TE0Q?KT:%2EE1%&VO3.,NB]:1$?,:#(K9JC
MUCB<I^SBQ]OIH_G:/4"I:Z1W(&A^N MF9INI98'G1"7][OK=#$SCCJ+IF_0^
M;20_AZP4LS-4YC-R=$/F1GC"C2T#S*S \__9]+!!+35G$S.$)V#,KI_Y5G]P
M_= -+$H-:,@&LEPQ@<W4J]L$^Q7-#0>;BTW<]J67?F=")S@3CRQ[6OG2M48D
M0$TR1FUWA)TO&_$3^ V@Z^:7358ZL'X3J!J42@HI-!NZHXJ0>405#[VG&.*P
M;?6=B@XD(_ZFYOJ FMDW.:@(!:YM&>C?//N7EF"ZZY;7L6JK)%HMH*Y*MC,,
M/!%>LKLQ85C47-M(/IRU3,M<68&E639P4B**4.4__RZ+O+2YE:=5 PF]YT+7
M35P\I"L%>/EXR#&395701:TLB((*?WA5-D1=U4P%JY)F%$4L%DG1,*G2P*_5
M5^UF1X72;41;V^XU&]WZ+NITJ]UZ9RNOO3U)E">1Y-TAN%.O]=J-;J/>0=7F
M+JK_JNU7FWMU5&L='S<ZG4:KN<)ZW/QR2)_'\L]J9[_1W.NVFAMH-U?+(9$O
MR,H*LPE?/@6UWUOMXW_^+13Y38;.EW7_=I-!<Y=YZ52[-K'OJZ7+EF1>C'_]
MX \;I!.=>^/+WJCZ!\#+W&', (NNX2=GB,<J..%V!0?JK5UO=E&[?M)J=U<B
M]_P8/HG\(,).B$(7=8A.92P62$%"KH^$PKKQ-7[@FB@<$%HH\L$O!8#K$WV
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M7%/D_-VGE]X(DEUS!EM824F>K*YLA"19: &C2C$77[9)$-DA6^C: K6>)/V
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M>>5:QNV1SEDH,Z^YQA1^!N'(WOY_4$L! A0#%     @ SH!=44?VYSY8 P
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M,#(P,3 R.65X.3DQ,S5E,S$Y+FAT;5!+ 0(4 Q0    ( ,Z 75&:]T.1@18
M ,FN   4              "  4P[  !P=&-T+3(P,C Q,#(Y>#AK+FAT;5!+
4!08     !0 % %$!  #_40     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
